Application of Pseudomonas aeruginosa in the preparation of intestinal repair preparations

Abstract

The present invention discloses an application of Phascolarctobacterium faecium in preparing an intestinal repair agent, wherein the Phascolarctobacterium faecium strain is used to prepare a probiotic repair agent for promoting the repair of intestinal flora disorders, an intestinal traumatic injury repair preparation, or a drug for preventing intestinal inflammation; in addition, the present invention also discloses an intestinal repair preparation, wherein the active ingredient comprises the Phascolarctobacterium faecium strain; the effective viable count of the Phascolarctobacterium faecium strain is 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g. In this concentration range, the strain has a significant effect on intestinal repair, and preferably also includes one or more combinations of succinic acid-producing probiotics, edible succinic acid-producing prebiotics and / or succinic acid and its salt compounds, especially Bacteroides thetaiotaomicron.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and more specifically, relates to an application of Pseudomonas aeruginosa in the preparation of an intestinal repair preparation. Background Art

[0002] Colonoscopy is a must for colorectal cancer physical examinations. In 2017, the US MSTF released new guidelines for colorectal cancer (CRC) screening: Colonoscopy and fecal immunochemical test (FIT) are the cornerstones of various screenings, and colonoscopy is the first choice. For high-risk groups, annual physical examinations are the most effective way to prevent early on; currently, large amounts of polyethylene glycol (PEG2000-4000) are used as laxatives and lubricants in colonoscopy; the large-scale use of PEG will cause long-term and irreversible damage to intestinal microorganisms, causing great harm to health.

[0003] For the general population, colonoscopy may cause: lasting effects on the composition of intestinal flora and homeostasis, including changes in the proportion of flora, some flora will completely disappear and must be supplemented exogenously to recover; intestinal mucosal damage. Colonoscopy is an invasive examination method, and the biggest harm is that it can easily damage the intestinal mucosa. After the examination, it is easy to have mild lower abdominal pain, bloating, indigestion and other symptoms, and even cause traumatic inflammation of the intestine. If there is inflammation or mucosal damage in the intestine, it is also easy to cause intestinal mucosal bleeding or perforation, infection and other complications.

[0004] For patients with lesions, in addition to the above-mentioned hazards, colonoscopy and surgery may also cause damage to the intestinal mucosa, resulting in wounds and susceptibility to infection, as well as the displacement of cancer cells.

[0005] In summary, there is a great potential hazard to human health after colonoscopy, and promoting bowel cleansing or intestinal repair after colonoscopy is very necessary to protect human health. However, there are few studies on promoting intestinal repair after colonoscopy, and no relevant reports have been seen so far. Summary of the invention

[0006] In view of the above defects or improvement needs of the prior art, the present invention provides an application of Phascolarctobacterium faecium in the preparation of intestinal repair preparations, the purpose of which is to discover that the Phascolarctobacterium faecium strain specifically promotes the repair of traumatic intestinal damage, especially the rapid repair of the intestine after colonoscopy, thereby solving the technical problems of slow recovery of the intestine after colonoscopy and easy to cause inflammation or infection.

[0007] To achieve the above object, according to one aspect of the present invention, there is provided a use of Phascolarctobacterium in preparing an intestinal repair agent, characterized in that the Phascolarctobacterium is a Phascolarctobacterium faecium strain.

[0008] Preferably, the use of Pseudomonas aeruginosa in the preparation of an intestinal repair agent is used to prepare a probiotic repair agent that promotes the repair of intestinal flora disorders, an intestinal traumatic injury repair preparation, or to prepare a drug for preventing intestinal inflammation.

[0009] Preferably, the use of Pseudomonas aeruginosa in the preparation of an intestinal repair agent is used to prepare a probiotic repair agent that promotes intestinal repair after colonoscopy.

[0010] Preferably, the use of the Phascolarctobacterium koalamensis in the preparation of an intestinal repair agent is used to prepare a probiotic for regulating intestinal flora imbalance after colonoscopy and / or a probiotic for enhancing resistance to intestinal inflammation or alleviating intestinal-related symptoms; the intestinal-related symptoms include mild lower abdominal pain, bloating, or weight loss caused by indigestion.

[0011] Preferably, the use of Phascolarctobacterium faecium in the preparation of an intestinal repair agent, wherein the effective viable count of the probiotic agent, Phascolarctobacterium faecium strain, is 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g.

[0012] According to another aspect of the present invention, an intestinal repair preparation is provided, wherein the active ingredient comprises a Phascolarctobacterium faecium strain; the effective viable count of the Phascolarctobacterium faecium strain is 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g.

[0013] Preferably, the active ingredients of the intestinal repair preparation further include one or more combinations of succinic acid-producing probiotics, edible succinic acid-producing prebiotics and / or compounds of succinic acid and its salts.

[0014] Preferably, the intestinal repair preparation, its active ingredients also include succinic acid-producing probiotics or one or more combinations of succinic acid.

[0015] Preferably, the intestinal repair preparation also includes Bacteroides thetaiotaomicron as an active ingredient, with an effective viable count of 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×1011 CFU / g.

[0016] Preferably, the intestinal repair preparation is an enteric solvent.

[0017] In general, the above technical solution conceived by the present invention is compared with the prior art, because it is found that the Phascolarctobacterium faecium strain can specifically and quickly repair the intestine after colonoscopy, and can achieve the following beneficial effects:

[0018] The present invention finds that the Phascolarctobacterium faecium strain has a significant effect on promoting the repair of intestinal traumatic damage or intestinal flora disorder, such as significantly promoting the repair of the intestine after colonoscopy, and can be used to prepare an intestinal repair agent, especially for preparing a probiotic repair agent for the intestine after colonoscopy. The experimental results show that compared with the control group, the Phascolarctobacterium faecium strain has a significant effect on promoting the repair of the intestine after colonoscopy, especially the effective viable count of 5×10 9 ~1×10 11 CFU / ml can solve the existing problems of slow intestinal recovery and susceptibility to infection after colonoscopy, and can be used to prepare intestinal repair preparations, especially when used in combination with Bacteroides thetaiotaomicron, it has a synergistic effect.

[0019] In addition, the present invention also found that the strain can enhance the resistance of the intestine to inflammation and can be used to prepare drugs for preventing intestinal-related inflammation, especially for preparing drugs for preventing post-colonoscopy intestinal inflammation. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Comparison of enriched bacterial flora between the slow recovery group (left) and the fast recovery group (right)

[0021] Figure 2 The weight ratio changes of mice in the control group and Pf strain group after colonoscopy (PEG) and DSS inflammation induction;

[0022] Figure 3 Effect of oral administration of Pf strain on body weight ratio of humanized mice after colonoscopy (PEG) and DSS inflammation induction

[0023] Figure 4 This is the HE staining of the colon of the control group mice (administered intragastrically with PBS) before (left) and after (right) DSS;

[0024] Figure 5 HE staining of the colon of humanized mice before DSS (left) and after DSS (right);

[0025] Figure 6 This is the HE staining of the colon of humanized mice after oral administration of Pf strain before DSS (left) and after DSS (right);

[0026] Figure 7 is the colitis score of mice in different treatment groups in the humanized mouse experiment;

[0027] Figure 8 It is a comparison of the absorbance values ​​of the Pf strain under different culture medium conditions; "-sodium succinate" means there is no sodium succinate in the culture medium; "+sodium succinate" means there is sodium succinate in the culture medium.

[0028] Fig. 9 The figure is the weight ratio change of mice treated with different strains. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0030] Traumatic intestinal injury can easily lead to local inflammation of the intestine, and even cause intestinal and systemic problems. Traumatic injuries include mechanical injuries to the intestinal mucosa caused by blunt compression, friction scratches, or sharp wounds, such as intestinal scratches caused by ingestion of foreign objects, incisions from intestinal-related surgeries, etc., especially common colonoscopy.

[0031] Colonoscopy is the gold standard for colorectal cancer screening. Colonoscopy must be performed during bowel cleansing. The most obvious change caused by this treatment is the removal of intestinal microorganisms, which destroys the intestinal microecological balance and causes a series of intestinal problems (such as long-term or irreversible damage to intestinal microorganisms, reduced immunity, etc.). This damage cannot be completely restored in the short term. At the same time, there are significant differences in the recovery ability of different people. The damaged intestinal environment is susceptible to invasion by inflammation and other conditions. Therefore, promoting the rapid recovery of the intestinal barrier after colonoscopy is beneficial to intestinal health and resistance to inflammation.

[0032] Traumatic intestinal injury causes damage to the intestinal mucosa and disrupts the original microecology of the intestine. In particular, the chemical environment in the intestine is complex, making it difficult for the microecology to colonize on the wound surface. Due to the special environment of the wound surface, harmful bacteria may even colonize and cause more serious inflammation or other adverse reactions.

[0033] Especially in the process of intestinal microbial flora remodeling after colonoscopy, how to recover quickly and recover in a favorable direction is a key link. The rapid recovery of intestinal microecology is the fastest way to supplement intestinal microorganisms, and some key bacteria play a vital role in intestinal remodeling.

[0034] Although intestinal flora has an important impact on intestinal health, the number of microorganisms in the intestine is huge and the flora is extremely complex. There are at least 1000 to 1150 types of bacteria, and the intestinal environment is extremely complex. The colonization effect of exogenous species in the intestine is difficult to determine, and its repair effect on the intestine after colonoscopy is also difficult to guarantee.

[0035] After a lot of experiments, we found that a strain of Phascolarctobacterium faecium, referred to as Pf bacteria, can significantly promote the repair of the intestine after colonoscopy, and can be used to prepare intestinal repair agents, especially to prepare probiotics that promote intestinal repair after colonoscopy. Furthermore, we also found that this strain can significantly enhance the resistance of the intestine to external inflammatory pressure, and can be used to prepare intestinal anti-inflammatory products, especially to prepare drugs for preventing intestinal inflammation, especially drugs for preventing intestinal related inflammation caused by colonoscopy.

[0036] The present invention provides an application of Pseudomonas aeruginosa in preparing an intestinal repair agent.

[0037] The application is used to prepare a probiotic repair agent that promotes the repair of intestinal flora disorders caused by mechanical intestinal operations or to prepare a drug for preventing intestinal inflammation, especially to prepare a probiotic repair agent that promotes intestinal repair after colonoscopy, especially to prepare a probiotic agent that regulates intestinal flora imbalance after colonoscopy and / or to prepare a probiotic agent that relieves intestinal mucosal damage or intestinal-related symptoms; the intestinal-related symptoms include mild lower abdominal pain, bloating, or weight loss caused by indigestion.

[0038] The effective viable count of the probiotic repair agent, Phascolarctobacterium faecium strain, is preferably 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g. In this concentration range, the strain has a significant effect on promoting intestinal repair.

[0039] The probiotic repair agent preferably also includes one or more combinations of succinic acid-producing probiotics, edible succinic acid-producing prebiotics and / or compounds of succinic acid and its salts; more preferably, it includes one or more combinations of succinic acid-producing probiotics or succinic acid. The use of succinic acid-producing probiotics or succinic acid can promote the proliferation of the strain and is more conducive to intestinal repair. In addition, adding a succinic acid-producing strain in combination with the strain has a synergistic effect and a better intestinal repair effect, such as Bacteroides thetaiotaomicron, referred to as Bt strain.

[0040] On the other hand, the present invention also provides an intestinal repair preparation, wherein the active ingredient of the intestinal repair preparation includes a Phascolarctobacterium faecium strain; the effective viable count of the Phascolarctobacterium faecium strain is 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g; preferably, the active ingredients also include one or more combinations of succinic acid-producing probiotics, edible succinic acid-producing prebiotics and / or succinic acid and its salt compounds; more preferably, the active ingredients also include succinic acid-producing probiotics or one or more combinations of succinic acid, especially Bacteroides thetaiotaomicron, and the effective viable count is preferably 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g.

[0041] The intestinal repair preparation is preferably a pharmaceutically acceptable enteric solvent.

[0042] The following are examples:

[0043] Example 1 Clinical sample long-term microbial flora big data analysis

[0044] By collecting stool and blood samples at different stages of clinical colonoscopy, performing metagenomic sequencing, and testing serum immunological indicators, and through bioinformatics analysis, it was found that the recovery trend of the intestinal flora of people after colonoscopy was inconsistent; through beta diversity analysis, the intestinal flora of people with different recovery speeds were analyzed and compared, and the different strains in the intestines of people with different recovery speeds were found.

[0045] The results are as follows Figure 1 , showing that the abundance of Pseudomonas aeruginosa pf strains was significantly higher in people who recovered faster than in those who recovered more slowly.

[0046] Example 2 Intestinal repair effect of Pf strain in PEG treatment and inflammation-induced mouse model

[0047] In the following examples, Pf bacteria is Phascolarctobacterium faecium JCM 30894 strain; DSS is dextran sulfate sodium; humanized mice are mice gavaged with slow fecal samples of intestinal repair; Bt bacteria is Bacteroides thetaiotaomicron; HFD is a high-fat diet. The above strains were purchased from Henan Industrial Microbial Strain Engineering Technology Research Center and Henan Beina Biological Inspection and Detection Co., Ltd.

[0048] PEG treatment: 200ul of polyethylene glycol solution containing polyethylene glycol 3350 (77.5 g / L), sodium chloride (1.9 g / L), sodium sulfate (7.4 g / L), potassium chloride (0.98 g / L) and sodium bicarbonate (2.2 g / L) diluted in sterile tap water was administered orally by gavage every 30 minutes for 2 hours. Fecal microbiota transfer was performed 6 hours after the last polyethylene glycol administration.

[0049] DSS treatment: 2% DSS was added to the drinking water of mice.

[0050] Preparation of Pf strain suspension: The fresh bacterial suspension from the second passage was inoculated into the liquid culture medium at a 2% (v / v) inoculation volume and cultured in an anaerobic constant temperature incubator at 37°C for about 24 hours. Centrifuge at 6000 rpm for 10 min, wash once with sterile saline, and then resuspend and shake with sterile saline to adjust the concentration of the bacterial suspension to 1×10 10 CFU / ml.

[0051] 40 6-week-old male C57BL / 6J mice (SPf grade), 5 mice per cage, were placed in a constant temperature of 25±2℃, relative humidity of 50±5%, and a 12 / 12h day and night cycle. After one week of adaptation to a normal diet (ND), the experimental mice ate a normal diet, during which the food intake was recorded weekly, and the body weight was weighed and randomly divided into groups. The mice were divided into two groups, 10 mice in each group, and PEG treatment was followed by gavage with 200ul of probiotic suspension every other day for a total of one week. After two weeks, 5 mice in each group were treated with DSS, and the weight changes and other inflammatory indicators of the mice were monitored. The results of the weight ratio change are shown in the table. Figure 2 Among them, the control group (PBS) consisted of mice fed with a normal diet (ND), and the Pf strain group was treated with PEG and then gavaged with Pf probiotic suspension.

[0052] Depend on Figure 2It can be seen that in the early stage, the weight ratio of the control group and the Pf strain group changed steadily, maintained at about 1, and there was no significant difference between the two groups; after DSS treatment, the weight ratios of mice in the control group and the oral gavage Pf strain group decreased, but the control group decreased significantly. The weight ratios of the control group and the Pf strain group showed a very significant difference. The weight ratio of mice in the Pf strain group was significantly larger than that in the control group, indicating that after DSS treatment, the degree of weight loss of mice gavaged with Pf strain was much smaller than that of the control group. It can be seen that oral gavage of Pf strain is beneficial to promote the recovery of mouse weight, which may be because oral gavage of Pf strain improves the appetite of mice. Of course, we can more intuitively see the promoting effect of Pf strain on intestinal repair after colonoscopy from the weight data.

[0053] Example 3 Intestinal repair effect of Pf strain in humanized mouse model induced by PEG treatment and inflammation

[0054] In order to simulate the human intestinal condition more realistically, based on Example 1, the mice were humanized, that is, the mice were transplanted with feces from the slow recovery group, and on this basis, they were treated with intestinal cleansing (PEG treatment) in clinical colonoscopy, and at the same time, DSS was used to induce mouse enteritis. The specific experiments are as follows:

[0055] Antibiotic treatment: The antibiotic solution was prepared by diluting ampicillin, neomycin, metronidazole and vancomycin with sterile water. Mice were given ampicillin, neomycin, metronidazole 200 mg / kg, and vancomycin 100 mg / kg once a day.

[0056] PEG treatment: 200ul of polyethylene glycol solution containing polyethylene glycol 3350 (77.5 g / L), sodium chloride (1.9 g / L), sodium sulfate (7.4 g / L), potassium chloride (0.98 g / L) and sodium bicarbonate (2.2 g / L) diluted in sterile tap water was administered orally by gavage every 30 minutes for 2 hours. Fecal microbiota transfer was performed 6 hours after the last polyethylene glycol administration.

[0057] DSS treatment: 2% DSS treatment for 7 days, with new DSS solution replaced every other day.

[0058] Preparation of Pf strain suspension: The fresh bacterial suspension from the second passage was inoculated into the liquid culture medium at a 2% (v / v) inoculation volume and cultured in an anaerobic constant temperature incubator at 37°C for about 24 hours. Centrifuge at 6000 rpm for 10 min, wash once with sterile saline, and then resuspend and shake with sterile saline to adjust the concentration of the bacterial suspension to 1×10 10 CFU / ml.

[0059] 40 6-week-old male C57BL / 6J mice (SPf grade), 5 mice per cage, were placed in a constant temperature of 25±2℃, relative humidity of 50±5%, and a 12 / 12h day and night cycle. After one week of adaptation to a normal diet (ND), the experimental mice ate a normal diet, and the food intake was recorded every week. The body weight was measured and the mice were randomly divided into groups. The mice were divided into two groups, 10 mice in each group, and treated with antibiotics for 8 days. After PEG treatment, fecal samples (slow recovery) + 200ul of probiotic suspension were gavaged every other day for a total of one week. After two weeks, 5 mice in each group were treated with DSS, and the weight changes and other inflammatory indicators of the mice were monitored. The changes in the weight ratio of the mice are shown in the figure. Figure 3 , HE staining of colon before DSS (left) and after DSS (right), see Figures 4 to 6 , mouse colitis score, see Figure 7 Among them, the control group (PBS) was composed of mice fed with a normal diet (ND), the humanized mouse group was composed of mice with fecal samples from the slow transplant recovery group, and the Pf strain group was composed of humanized mice treated with PEG and then gavaged with Pf strain probiotic suspension.

[0060] Depend on Figure 3 It can be seen that after grouping and DSS treatment, the weight ratio of the three groups of mice, namely the control group, humanized mouse group and Pf strain group, decreased, and there were obvious differences in the weight ratios of the three groups, among which the weight ratio of the Pf strain group was > the control group > the humanized mouse group, and the weight ratio of the Pf strain group was 0.9 5 days after DSS treatment. It can be seen that the weight loss of mice in the Pf strain group was extremely mild; and the weight ratio of the humanized mouse group was 0.8 5 days after DSS treatment, indicating that the Pf strain can improve the adverse factors of slow intestinal recovery in humanized mice, and further illustrate that the Pf strain can significantly promote intestinal repair.

[0061] Depend on Figures 4 to 6 It can be seen that the above three groups of colon HE staining images have significant differences. Figures 4 to 6 It can be seen that after DSS treatment, the colon mucosal layers of the three groups had different degrees of damage and inflammatory cell infiltration. Among them, the tolerance of the humanized mouse group to DSS was obviously much weaker than that of the control group. The colon was severely damaged and there was significant inflammatory infiltration. Compared with the control group, the humanized mice in the Pf strain group had a stronger tolerance to DSS after gavage with the Pf strain, and the damage to the colon was reduced. Among the three groups, the inflammatory cell infiltration in the pf strain group was the lightest. It can be seen that after gavage with the Pf strain, the intestinal resistance of the mice to inflammation was significantly better than that of the other groups, which further illustrates that in humanized mice, the Pf strain has a significant promoting effect on intestinal repair after colonoscopy and can significantly enhance the intestinal resistance to inflammation.

[0062] Depend on Figure 7It can be seen that the colitis scores of mice in each group after DSS treatment were significantly higher than those in the group without DSS treatment, indicating that the DSS-induced inflammation model was successfully established; after DSS treatment, the colitis score of mice in the Pf strain group was < that of the control group < that of the humanized mouse group, among which there was a significant difference in the colitis scores between the oral gavage Pf strain group and the humanized mouse group, indicating that oral gavage of the Pf strain can significantly enhance the intestine's resistance to inflammation, and the Pf strain can significantly improve the symptoms of intestinal inflammation.

[0063] In summary, whether it is intuitively seen from the body weight or from the HE staining images of the mouse colon and the colon inflammation score, it has been shown that oral gavage of Pf strain has a significant promoting effect on intestinal repair after colonoscopy and can significantly enhance the intestine's resistance to external inflammatory pressure.

[0064] Example 4 In vitro growth promotion experiment of Pf strain

[0065] Culture medium (-sodium succinate):

[0066] Tryptone 5g, meat peptone 5g, yeast extract 10g, saline solution 40ml, resazurin (0.1% w / v) 0.5ml, Na2CO3 1.0g, glucose 8g, distilled water to 1L, pH adjusted to 7.0;

[0067] Salt solution: CaCl2 2H2O 0.25g, MgSO4 7H2O 0.5g, K2HPO4 1.0g, KH2PO4 1.0g, NaHCO3 10g, NaCl 2g, distilled water to 1L.

[0068] Culture medium (+ sodium succinate):

[0069] Tryptone 5g, meat peptone 5g, yeast extract 10g, saline solution 40ml, resazurin (0.1% w / v) 0.5ml, Na2CO3 1.0g, sodium succinate 8g, distilled water to 1L, pH adjusted to 7.0;

[0070] Salt solution: CaCl2 2H2O 0.25g, MgSO4 7H2O 0.5g, K2HPO4 1.0g, KH2PO4 1.0g, NaHCO3 10g, NaCl 2g, distilled water to 1L.

[0071] The Pf strain was cultured in medium (-sodium succinate) and medium (+sodium succinate), and the absorbance values ​​of the strain were shown in Table 1. Figure 8 .

[0072] Depend on Figure 8It can be seen that in the culture medium with added sodium succinate, the Pf strain can grow normally, and in the culture medium lacking sodium succinate, the Pf strain cannot grow, indicating that succinic acid or sodium succinate is the carbon source necessary for its growth. It can be seen that adding succinic acid-producing probiotics or edible succinic acid-producing prebiotics or products containing succinic acid and its salts is beneficial to the growth of intestinal Pf strains, which can indirectly promote intestinal repair and may also enhance the intestinal resistance to inflammation.

[0073] It can be seen from this that the probiotic agent that is compounded with the Pf strain and succinic acid-producing probiotics or edible succinic acid-producing prebiotics or one or more of succinic acid and its salts has a better effect on intestinal repair.

[0074] Example 5 Effects of different bacterial strain treatments on intestinal repair in mice

[0075] Experimental groups: HFD+PEG+PBS (control group), HFD+PEG+Pf, HFD+PEG+Pf+Bt

[0076] Experimental method: Except that the mice were fed a high-fat diet (HFD), the rest of the operation was the same as in Example 2. The changes in the weight ratio of the mice were shown in Fig. 9 .

[0077] Depend on Fig. 9 The results showed that there were significant differences in the weight changes of the three groups of mice. The degree of weight loss of mice was HFD+PEG+PBS, HFD+PEG+Pf, and HFD+PEG+Pf+Bt from high to low. It can be seen that the simultaneous addition of Pf bacteria and Bt bacteria has a significant inhibitory effect on the weight loss of mice, and its inhibitory effect is better than that of Pf bacteria alone, indicating that the combined use of Pf bacteria and Bt bacteria has a synergistic effect, and its repair effect on the mouse intestine is faster and better than that of Pf bacteria alone.

[0078] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of a composition containing Phascolarctobacterium koalamensis in the preparation of an intestinal repair agent, characterized in that: The composition includes Pseudomonas aeruginosa Phascolarctobacterium faecium JCM 30894 strain, with an effective viable count of 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g, which is used to prepare probiotics for regulating the imbalance of intestinal flora after colonoscopy with PEG bowel cleansing treatment.

2. A PEG bowel cleansing treatment and intestinal repair preparation after colonoscopy, characterized in that: Its active ingredients include Pseudomonas aeruginosa Phascolarctobacterium faecium JCM 30894 strain; Phascolarctobacterium faecium The effective viable count of JCM 30894 strain was 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g.

3. The intestinal repair preparation according to claim 2, characterized in that: Its active ingredients also include Bacteroides thetaiotaomicron bacteria, the effective viable count is 5×10 9 ~1×10 11 CFU / ml or 5×10 9 ~1×10 11 CFU / g.

Images